VNDA MEXC RealStocks
Own real VNDA shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-16 13:22:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Vanda Pharmaceuticals Inc. (VNDA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.03, with a market capitalization of $241.27M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.57 to $9.94. This page covers its latest market performance, valuation, price trends and company information.
$241.27M | |
$4.03 | |
$4.03 | |
$4.03 | |
$3.99 | |
33.00 | |
1.06M | |
-- | |
$9.94 | |
$3.57 | |
-- | |
-- |
Vanda Pharmaceuticals Inc. (VNDA) is trading at $4.03 in pre-market trading as of 2026-11-16 13:18:00, up 0.88% ($0.04) from the previous close of $3.99
Pre-market trading shows how investors are pricing VNDA before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Vanda Pharmaceuticals Inc. (VNDA) moved from $3.59 to $4.03, representing a gain of 12.12% ($0.44).
The stock traded between $3.57 and $4.20 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1.14 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 7.2%
VNDA is currently trading at $4.03, placing it 7.2% of the way from its 52-week low of $3.57 to its 52-week high of $9.94. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 533 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vanda Pharmaceuticals Inc. (VNDA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to VNDA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between VNDA shares and USD.
VNDA Shares to USD
1.00 VNDA shares = 4.025 USD
Calculations are estimates based on the latest available price and are for reference only.